FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Fiche publication
Date publication
juin 2016
Journal
The Lancet. Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CONROY Thierry
Tous les auteurs :
Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Groot Koerkamp B
Lien Pubmed
Résumé
35% of patients with pancreatic cancer have unresectable locally advanced disease at diagnosis. Several studies have examined systemic chemotherapy with FOLFIRINOX (leucovorin and fluorouracil plus irinotecan and oxaliplatin) in patients with locally advanced pancreatic cancer. We aimed to assess the effectiveness of FOLFIRINOX as first-line treatment in this patient population.
Mots clés
Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Camptothecin, administration & dosage, Chemotherapy, Adjuvant, Deoxycytidine, administration & dosage, Fluorouracil, administration & dosage, Humans, Irinotecan, Leucovorin, administration & dosage, Neoplasm Staging, Organoplatinum Compounds, administration & dosage, Oxaliplatin, Pancreatic Neoplasms, drug therapy, Prognosis, Survival Rate
Référence
Lancet Oncol.. 2016 Jun;17(6):801-10